Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial

[1]  Peter Sandercock,et al.  The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke , 2008, Trials.

[2]  R. Shinton.  Questions about authorisation of alteplase for ischaemic stroke , 2014, The Lancet.

[3]  Eric Manheimer,et al.  Thrombolysis in acute ischaemic stroke: time for a rethink? , 2015, BMJ : British Medical Journal.

[4]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[5]  Geoff Cohen,et al.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.

[6]  P. Sandercock,et al.  Statistical Analysis Plan for the Third International Stroke Trial (IST-3); Part of a ‘Thread’ of Reports of the Trial , 2012, International journal of stroke : official journal of the International Stroke Society.

[7]  R. Lindley,et al.  Thrombolysis for acute ischaemic stroke: consumer involvement in design of new randomised controlled trial , 2002, BMJ : British Medical Journal.

[8]  G. Hankey,et al.  Do risks outweigh benefits in thrombolysis for stroke? , 2013, BMJ.

[9]  J. Wardlaw,et al.  A simple practical classification of cerebral infarcts on CT and its interobserver reliability. , 1994, AJNR. American journal of neuroradiology.

[10]  Joanna M. Wardlaw,et al.  Alteplase for Acute Ischemic Stroke: Outcomes by Clinically Important Subgroups in the Third International Stroke Trial , 2015, Stroke.

[11]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.,et al.  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[12]  P. Sandercock,et al.  Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited , 2011, Trials.

[13]  P. Sandercock.  Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial , 2013, The Lancet Neurology.

[14]  P. Sandercock,et al.  Functional Status Three Months after the First Ischemic Stroke Is Associated with Long-Term Outcome: Data from a Community-Based Cohort , 2014, Cerebrovascular Diseases.

[15]  Joseph P. Broderick,et al.  Effects of tissue plasminogen activator for acute ischemic stroke at one year , 1999 .

[16]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[17]  P. Dorman,et al.  Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies , 2008, BMJ : British Medical Journal.

[18]  The benefi ts and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke ( the third international stroke trial [ IST-3 ] ) : a randomised controlled trial , 2012 .

[19]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[20]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[21]  W. Hacke,et al.  Mechanical thrombectomy in acute ischemic stroke: Consensus statement by ESO-Karolinska Stroke Update 2014/2015, supported by ESO, ESMINT, ESNR and EAN , 2016, International journal of stroke : official journal of the International Stroke Society.

[22]  Harlan M Krumholz,et al.  Increasing value and reducing waste: addressing inaccessible research , 2014, The Lancet.

[23]  P. Sandercock,et al.  Effect of Alteplase Within 6 Hours of Acute Ischemic Stroke on All-Cause Mortality (Third International Stroke Trial) , 2014, Stroke.

[24]  P. Sandercock,et al.  Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .